Use of ATR inhibitors as single-agent treatments are being investigated in an ongoing phase II clinical trial involving patients with ARID1A loss in gynecological cancer treated with an ATR-inhibitor in combination with olaparib (NCT04065269) (Refer to Table 6). The gene discussed is ATR; the disease is female reproductive organ cancer.